Role of fluorine 18 fluorodeoxyglucose positron emission tomography-computed tomography in focal and generalized infectious and inflammatory disorders

Clinical Infectious Diseases

Volumn 54, Issue 9, 2012, Pages 1333-1341

  Haroon, Athar ^a   Zumla, Alimuddin ^b   Bomanji, Jamshed ^a  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ARTICLE; BACTERIAL ENDOCARDITIS; CENTRAL NERVOUS SYSTEM; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIABETIC FOOT; DISKITIS; GRAFT INFECTION; HUMAN; INFECTION; INFLAMMATORY CELL; INFLAMMATORY DISEASE; METABOLISM; METAL IMPLANTATION; MYCOSIS; OSTEOMYELITIS; PERICARDITIS; PLEURA; PLEURA CAVITY; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; SARCOIDOSIS; TREATMENT RESPONSE; TUBERCULOSIS; VASCULITIS;

COMMUNICABLE DISEASES; FLUORODEOXYGLUCOSE F18; HUMANS; INFLAMMATION; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84859735376     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis193     Document Type: Article

References (75)

1. Keidar Z, Engel A, Hoffman A, Israel O, Nitecki S. Prosthetic vascular graft infection: the role of 18F-FDG PET/CT. J Nucl Med 2007; 48: 1230-6. (Pubitemid 47242786)
2. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol 1927; 8:519.
3. Avril N, Menzel M, Dose J, et al. Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med 2001; 42:9.
4. Ak I, Stokkel MP, Pauwels EK. Positron emission tomography with 2-[18 F] fluoro-2-deoxy-D-glucose in oncology. J Cancer Res Clin Oncol 2000; 126:560-74.
5. Lehmann K, Behe M, Meller J, Becker W. F-18-FDG uptake in granulocytes: basis of F-18-FDG scintigraphy for imaging infection. J Nucl Med 2001; 42:1384.
6. Chakrabarti R, Jung CY, Lee TP, Liu H, Mookerjee BK. Changes in glucose transport and transporter isoforms during the activation of human peripheral blood lymphocytes by phytohemagglutinin. J Immunol 1994; 152:2660.
7. Gamelli RL, Liu H, He LK, Hofmann CA. Augmentations of glucose uptake and glucose transporter-1 in macrophages following thermal injury and sepsis in mice. J Leukoc Biol 1996; 59:639.
8. Ahmed N, Kansara M, Berridge MV. Acute regulation of glucose transport in a monocyte-macrophage cell line: Glut-3 affinity for glucose is enhanced during the respiratory burst. Biochem J 1997; 327:369.
9. Becker W, Meller J. The role of nuclear medicine in infection and inflammation. Lancet Infect Dis 2001; 1:326-33. (Pubitemid 33586613)
10. De Winter F, Vogelaers D, Gemmel F, Dierckx RA. Promising role of 18-F-fluoro-D-deoxyglucose positron emission tomography in clinical infectious diseases. Eur J Clin Microbiol Infect Dis 2002; 21:247-57. (Pubitemid 34507868)
11. Lin. PET and PET/CT: a clinical guide. 2nd ed. 2009. Thieme Medical Publishers, Inc.
12. Bonardel G, Carmoi T, Gontier E, et al. [Use of positron emission tomography in sarcoidosis [in French]. Rev Med Interne 2011; 32:101-8.
13. Balan A, Hoey ET, Sheerin F, Lakkaraju A, Chowdhury FU. Multitechnique imaging of sarcoidosis. Clin Radiol 2010; 65:750-60.
14. Chowdhury FU, Sheerin F, Bradley KM, Gleeson FV. Sarcoid-like reaction to malignancy on whole-body integrated (18)F-FDG PET/CT: prevalence and disease pattern. Clin Radiol 2009; 64:675-81.
15. Kim S, Im HJ, Kim W, Kim T, Hwangbo B, Kim HJ. F-18 fluorodeoxyglucose and F-18 fluorothymidine positron emission tomography/computed tomography imaging in a case of neurosarcoidosis. Clin Nucl Med 2010; 35:67-70.
16. El-Haddad G, Zhuang H, Gupta N, Alavi A. Evolving role of positron emission tomography in the management of patients with inflammatory and other benign disorders. Semin Nucl Med 2004; 34:313-29. (Pubitemid 39366000)
17. Teirstein AS, Machac J, Almeida O, Lu P, Padilla ML, Iannuzzi MC. Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest 2007; 132:1949-53.
18. Aberg C, Ponzo F, Raphael B, Amorosi E, Moran V, Kramer E. FDG positron emission tomography of bone involvement in sarcoidosis. AJR Am J Roentgenol 2004; 182:975-7. (Pubitemid 38391661)
19. Bolat S, Berding G, Dengler R, Stangel M, Trebst C. Fluorodeoxyglucose positron emission tomography (FDG-PET) is useful in the diagnosis of neurosarcoidosis. J Neurol Sci 2009; 287:257-9.
20. Okumura W, Iwasaki T, Ueda T, et al. Usefulness of 18F-FDG PET for diagnosis of cardiac sarcoidosis [in Japanese]. Kaku Igaku 1999; 36:341-8. (Pubitemid 29318390)
21. Hofmeyr A, Eddie Lau WF, Slavin MA. Mycobacterium tuberculosis infection in patients with cancer, the role of 18-fluorodeoxyglucose positron emission tomography for diagnosis and monitoring treatment response. Tuberculosis (Edinb) 2007; 87:459-63. (Pubitemid 47314357)
22. Horsburgh CR. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med 2004; 350:2060-7.
23. Bakheet S, Powe J, Ezzat A, Rostom A. F-18-FDG uptake in tuberculosis. Clin Nucl Med 1998; 23:739.
24. Piana F, Codecasa LR, Cavallerio P, et al. Use of a T-cell-based test for detection of tuberculosis infection among immunocompromised patients. Eur Respir J 2006; 28:31-4. (Pubitemid 44914257)
25. Mahfouz T, Miceli MH, Saghafifar F, et al. 18F-fluorodeoxyglucose positron emission tomography contributes to the diagnosis and management of infections in patients with multiple myeloma: a study of 165 infectious episodes. J Clin Oncol 2005; 23:7857-63. (Pubitemid 46661462)
26. Cohn DL, O'Brien RJ, Geiter LJ, et al. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 2000; 161:S221-47.
27. Shrikanthan S, Aydin A, Dhurairaj T, Alavi A, Zhuang H. Intense esophageal FDG activity caused by Candida infection obscured the concurrent primary esophageal cancer on PET imaging. Clin Nucl Med 2005; 30:695.
28. Lee DG, Choi JH, Kim YJ, et al. Hepatosplenic tuberculosis mimicking disseminated candidiasis in patients with acute leukemia. Int J Hematol 2001; 73:119-21.
29. Xu B, Shi P, Wu H, Guo X, Wang Q, Zhou S. Utility of FDG PET/CT in guiding antifungal therapy in acute leukemia patients with chronic disseminated candidiasis. Clin Nucl Med 2010; 35:567.
30. Yen RF, Chen ML, Liu FY, et al. False-positive 2-[F-18]-fluoro-2-deoxy-D- glucose positron emission tomography studies for evaluation of focal pulmonary abnormalities. J Formos Med Assoc 1998; 97:642-5.
31. Kapucu LO, Meltzer CC, Townsend DW, Keenan RJ, Luketich JD. Fluorine-18-fluorodeoxyglucose uptake in pneumonia. J Nucl Med 1998; 39:1267.
32. Ozsahin H, von Planta M, Müller I, et al. Successful treatment of invasive aspergillosis in chronic granulomatous disease by bone marrow transplantation, granulocyte colony-stimulating factor-mobilized granulocytes, and liposomal amphotericin-B. Blood 1998; 92:2719-24. (Pubitemid 28469084)
33. Taylor IK, Hill AA, Hayes M, et al. Imaging allergen-invoked airway inflammation in atopic asthma with [18F]-fluorodeoxyglucose and positron emission tomography. Lancet 1996; 347:937-40.
34. Imran MB, Kubota K, Yoshioka S, et al. Sclerosing mediastinitis: findings on fluorine-18 fluorodeoxyglucose positron emission tomography. Clin Nucl Med 1999; 24:305-8. (Pubitemid 29200703)
35. Oh JK, Ahn MI, Kim CH, et al. The value of F-18 FDG-PET/CT in diagnosis of chronic empyema-associated malignancy. Clin Radiol 2008; 63:1177-80.
36. Minami M, Kawauchi N, Yoshikawa K, et al. Malignancy associated with chronic empyema: radiologic assessment. Radiology 1991; 178: 417.
37. Cattaneo SM, Klassen KP. Carcinoma of the chest wall complicating chronically draining empyema. Chest 1973; 64:673.
38. Duysinx B, Nguyen D, Louis R, et al. Evaluation of pleural disease with 18-fluorodeoxyglucose positron emission tomography imaging. Chest 2004; 125:489.
39. Kramer H, Pieterman RM, Slebos DJ, et al. PET for the evaluation of pleural thickening observed on CT. J Nucl Med 2004; 45:995.
40. Strobel K, Stumpe KD. PET/CT in musculoskeletal infection. Semin Musculoskelet Radiol 2007; 11:353.
41. Hartmann A, Eid K, Dora C, Trentz O, von Schulthess GK, Stumpe KD. Diagnostic value of 18 F-FDG PET/CT in trauma patients with suspected chronic osteomyelitis. Eur J Nucl Med Mol Imaging 2007; 34:704-14. (Pubitemid 46669361)
42. Guhlmann A, Brecht-Krauss D, Suger G, et al. Fluorine-18-FDG PET and technetium-99m antigranulocyte antibody scintigraphy in chronic osteomyelitis. J Nucl Med 1998; 39:2145.
43. Modic MT, Steinberg PM, Ross JS, Masaryk TJ, Carter JR. Degenerative disk disease: assessment of changes in vertebral body marrow with MR imaging. Radiology 1988; 166:193-9. (Pubitemid 18027070)
44. Gemmel F, Rijk PC, Collins JMP, Parlevliet T, Stumpe KD, Palestro CJ. Expanding role of 18F-fluoro-d-deoxyglucose PET and PET/CT in spinal infections. Eur Spine J 2010; 19:540-51.
45. Stumpe KD, Zanetti M, Weishaupt D, Hodler J, Boos N, von Schulthess GK. FDG positron emission tomography for differentiation of degenerative and infectious endplate abnormalities in the lumbar spine detected on MR imaging. AJR Am J Roentgenol 2002; 179:1151.
46. Sofka CM, Potter HG, Adler RS, Pavlov H. Musculoskeletal imaging update: current applications of advanced imaging techniques to evaluate the early and long-term complications of patients with orthopedic implants. HSS J 2006; 2:73-7. (Pubitemid 44421785)
47. van der Bruggen W, Bleeker-Rovers CP, Boerman OC, Gotthardt M, Oyen WJ. PET and SPECT in osteomyelitis and prosthetic bone and joint infections: a systematic review. Semin Nucl Med 2010; 40:3-15.
48. Manthey N, Reinhard P, Moog F, Knesewitsch P, Hahn K, Tatsch K. The use of [18 F]fluorodeoxyglucose positron emission tomography to differentiate between synovitis, loosening and infection of hip and knee prostheses. Nucl Med Commun 2002; 23:645-53. (Pubitemid 34748004)
49. Nawaz A, Torigian DA, Siegelman ES, Basu S, Chryssikos T, Alavi A. Diagnostic performance of FDG-PET, MRI, and plain film radiography (PFR) for the diagnosis of osteomyelitis in the diabetic foot. Mol Imaging Biol 2010; 12:335-42.
50. Hill EE, Herijgers P, Claus P, Vanderschueren S, Peetermans WE, Herregods MC. Clinical and echocardiographic risk factors for embolism and mortality in infective endocarditis. Eur J Clin Microbiol Infect Dis 2008; 27:1159-64.
51. Vind SH, Hess S. Possible role of PET/CT in infective endocarditis. J Nucl Cardiol 2010; 17:516-19.
52. Bleeker-Rovers CP, Vos FJ, Wanten GJA, et al. 18F-FDG PET in detecting metastatic infectious disease. J Nucl Med 2005; 46:2014-19. (Pubitemid 46657448)
53. Ben-Haim S, Gacinovic S, Israel O. Cardiovascular infection and inflammation. Semin Nucl Med 2009; 39:103-14.
54. Testempassi E, Kubota K, Morooka M, et al. Constrictive tuberculous pericarditis diagnosed using 18F-fluorodeoxyglucose positron emission tomography: a report of two cases. Ann Nucl Med 2010; 24:421-5.
55. Meller J, Sahlmann C, Scheel AK. 18F-FDG PET and PET/CT in fever of unknown origin. J Nucl Med 2007; 48:35-45. (Pubitemid 47555372)
56. Meller J, Altenvoerde G, Munzel U, et al. Fever of unknown origin: prospective comparison of [18F]FDG imaging with a double-head coincidence camera and gallium-67 citrate SPET. Eur J Nucl Med 2000; 27:1617-25.
57. Kjaer A, Lebech A, Eigtved A, Højgaard L. Fever of unknown origin: prospective comparison of diagnostic value of 18F-FDG PET and 111Ingranulocyte scintigraphy. Eur J Nucl Med Mol Imaging 2004; 31:622-6. (Pubitemid 38647899)
58. Blockmans D, Coudyzer W, Vanderschueren S, et al. Relationship between fluorodeoxyglucose uptake in the large vessels and late aortic diameter in giant cell arteritis. Rheumatology (Oxford) 2008; 47:1179-84. (Pubitemid 352038223)
59. Kobayashi Y, Ishii K, Oda K, et al. Aortic wall inflammation due to Takayasu arteritis imaged with 18F-FDG PET coregistered with enhanced CT. J Nucl Med 2005; 46:917-22. (Pubitemid 43733504)
60. Belhocine T, Blockmans D, Hustinx R, Vandevivere J, Mortelmans L. Imaging of large vessel vasculitis with (18)FDG PET: illusion or reality? A critical review of the literature data. Eur J Nucl Med Mol Imaging 2003; 30:1305-13. (Pubitemid 37205389)
61. Blockmans D, Maes A, Stroobants S, et al. New arguments for a vasculitic nature of polymyalgia rheumatica using positron emission tomography. Rheumatology (Oxford) 1999; 38:444-7. (Pubitemid 29507129)
62. Blockmans D, Stroobants S, Maes A, Mortelmans L. Positron emission tomography in giant cell arteritis and polymyalgia rheumatica: evidence for inflammation of the aortic arch. Am J Med 2000; 108:246-9. (Pubitemid 30100617)
63. Orton DF, LeVeen RF, Saigh JA, et al. Aortic prosthetic graft infections: radiologic manifestations and implications for management1. Radiographics 2000; 20:977-93.
64. Hoffman JM, Waskin HA, Schifter T, et al. FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS. J Nucl Med 1993; 34:567.
65. Mascarenhas NB, Lam D, Lynch GR, Fisher RE. PET imaging of cerebral and pulmonary Nocardia infection. Clin Nuc Med 2006; 31:131.
66. Sasaki M, Ichiya Y, Kuwabara Y, et al. Ringlike uptake of [18F]FDG in brain abscess: a PET study. J Comput Assist Tomogr 1990; 14: 486-7. (Pubitemid 20162584)
67. Newberg A, Hassan A, Alavi A. Cerebral metabolic changes associated with Lyme disease. Nucl Med Commun 2002; 23:773-7. (Pubitemid 34837008)
68. Federici L, Blondet C, Imperiale A, et al. Value of 18F-FDG-PET/CT in patients with fever of unknown origin and unexplained prolonged inflammatory syndrome: a single centre analysis experience. Int J Clin Pract 2010; 64:55-60.
69. Bleeker-Rovers CP, Vos FJ, Mudde AH, et al. A prospective multicentre study of the value of FDG-PET as part of a structured diagnostic protocol in patients with fever of unknown origin. Eur J Nucl Med Mol Imaging 2007; 34:694-703. (Pubitemid 46669364)
70. Buysschaert I, Vanderschueren S, Blockmans D, Mortelmans L, Knockaert D. Contribution of (18)fluoro-deoxyglucose positron emission tomography to the work-up of patients with fever of unknown origin. Eur J Intern Med 2004; 15:151-6. (Pubitemid 38900559)
71. Bleeker-Rovers CP, Vos FJ, de Kleijn EMHA, et al. A prospective multicenter study on fever of unknown origin. Medicine (Baltimore) 2007; 86:26-38.
72. Derdelinckx I, Maes A, Bogaert J, Mortelmans L, Blockmans D. Positron emission tomography scan in the diagnosis and follow-up of aortitis of the thoracic aorta. Acta Cardiol 2000; 55:193-5. (Pubitemid 30411856)
73. Blockmans D, Knockaert D, Maes A, et al. Clinical value of [18F]fluorodeoxyglucose positron emission tomography for patients with fever of unknown origin. Clin Infect Dis 2001; 32:191-6. (Pubitemid 32524787)
74. Barry CE, Boshoff HI, Dartois V, et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 2009; 7:845-55.
75. Groves AM, Win T, Haim SB, Ell PJ. Non-[18F]FDG PET in clinical oncology. Lancet Oncol 2007; 8:822-30. (Pubitemid 47308671)